Nymox

December 1, 2016December 1, 2016

Nymox Reports Positive New Results from Phase 3 Studies of Possible BPH Treatment

News

Nymox Pharmaceutical Corporation announced new, prospective and randomized results from Phase 3 clinical trial with its lead drug candidate NX-1207 (fexapotide triflutate) for the treatment of benign prostate enlargement (BPH). Findings confirming ... Read more

December 17, 2015December 17, 2015

Topline Data from BPH Extension Studies Show Safety, Efficacy of Single-Injection Treatment

News

Nymox Pharmaceutical Corp. has announced that its long-term extension prospective double-blind Phase 3 clinical trials of fexapotide triflutate (NX-1207) as a single-injection treatment in benign prostatic hyperplasia (BPH) patients have met their primary ... Read more